Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Andrea Shapiro"'
Autor:
Peter Nash, Yoshiya Tanaka, Kevin L Winthrop, Eun Bong Lee, Xavier Mariette, Jeffrey R Curtis, Kenneth Kwok, Connie Chen, Pinaki Biswas, Lisy Wang, Christina Charles-Schoeman, Ann Madsen, Stanley B Cohen, Andrea Shapiro, Jürgen Wollenhaupt
Publikováno v:
RMD Open, Vol 6, Iss 3 (2020)
Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term e
Externí odkaz:
https://doaj.org/article/06d315c88fb8416d89479fa698afb87f
Autor:
Hendrik Schulze-Koops, Andrea Shapiro, Dimitrios A. Pappas, Kevin L. Winthrop, Harry Shi, David Gold, D. Henrohn, Gustavo Citera, Alina Onofrei, Carol A. Connell
Publikováno v:
Annals of the Rheumatic Diseases
A randomised, open-label, blinded endpoint post-authorisation safety study (Study A3921133; NCT02092467; database not locked and subject to change) evaluated the safety of tofacitinib 5 mg and 10 mg twice daily (BID) versus tumour necrosis factor inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f929ad5e7d94ef5de38d1d0ecbbbbbf
http://europepmc.org/articles/PMC7788057
http://europepmc.org/articles/PMC7788057
Autor:
Andrea Shapiro
In 1948 World War II veteran Earl Shaffer decided to “walk the war out of his system” and became the first person to report hiking the entire length of the Appalachian Trail in one, continuous journey. This children's book tells the story of Earl
Autor:
Christina Charles-Schoeman, Yoshiya Tanaka, Kenneth Kwok, Peter Nash, Kevin L. Winthrop, Pinaki Biswas, Andrea Shapiro, Jeffrey R. Curtis, Lisy Wang, Ann Madsen, Connie Chen, Xavier Mariette, Stanley Cohen, Jürgen Wollenhaupt, Eun Bong Lee
Publikováno v:
RMD Open
RMD Open, Vol 6, Iss 3 (2020)
RMD Open, Vol 6, Iss 3 (2020)
ObjectiveTofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08f56e8673be64735729496f3acc35c0
http://europepmc.org/articles/PMC7722371
http://europepmc.org/articles/PMC7722371
Autor:
Heather J. Litman, Andrea Shapiro, Christine J. Barr, Clifton O. Bingham, Jeff Greenberg, Carol A. Connell, Arthur Kavanaugh, Dimitrios A. Pappas, Jamie Geier, Jose Luis Rivas, Alina Onofrei, Laura C. Cappelli, Joel M. Kremer, Kimberly J. Dandreo, Ann Madsen
Publikováno v:
ACR Open Rheumatology
ACR Open Rheumatology, Vol 3, Iss 3, Pp 173-184 (2021)
ACR Open Rheumatology, Vol 3, Iss 3, Pp 173-184 (2021)
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5-year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease-mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf4c2563a88b4a2fe74cf337ced5cbc8
https://pubmed.ncbi.nlm.nih.gov/33570260
https://pubmed.ncbi.nlm.nih.gov/33570260
Autor:
M. Galindo-Izquierdo, Stanley Cohen, Andrea Shapiro, D. Henrohn, S. Marsal, A. Yndestad, Kevin L. Winthrop, Annette Diehl, H. Jo
Publikováno v:
Annals of the Rheumatic Diseases. 80:1149-1150
Background:Patients (pts) with rheumatoid arthritis (RA) have an increased susceptibility to seasonal influenza and its complications.1 In light of the COVID-19 pandemic, there is a need to better understand acute respiratory viral RNA infections, su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8420d892d75dc86fa91a6944f0e74a9
https://doi.org/10.1136/annrheumdis-2021-eular.361
https://doi.org/10.1136/annrheumdis-2021-eular.361
Autor:
David Gold, Harry Shi, Andrea Shapiro, Lisy Wang, Gustavo Citera, D. Henrohn, Kevin L. Winthrop, Hendrik Schulze-Koops
Publikováno v:
Annals of the Rheumatic Diseases. 79:1007-1008
Background:Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). A recent ad hoc safety analysis (as of August 2019; may be subject to change) from an ongoing, open-label, randomised, post-authorisation safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51d23a00346eb754438c1aa57ee8a3fb
https://doi.org/10.1136/annrheumdis-2020-eular.1432
https://doi.org/10.1136/annrheumdis-2020-eular.1432
Autor:
David Gold, John Woolcott, Juergen Wollenhaupt, Ara Dikranian, Peter Nash, Lisy Wang, Andrea Shapiro, Harry Shi, Louis Bessette, Jose Luis Rivas, Valderílio Feijó Azevedo
Publikováno v:
Abstracts Accepted for Publication.
Background: Tolerability remains ill-defined in clinical trials and commonly refers to non-serious adverse events (AEs) impacting patient (pt) satisfaction and treatment adherence. Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::765ff17406f4723724c8e23999f4d313
https://doi.org/10.1136/annrheumdis-2019-eular.418
https://doi.org/10.1136/annrheumdis-2019-eular.418
Autor:
Laura C. Cappelli, Jeff Greenberg, Dimitrios A. Pappas, Connie Chen, Kimberly J. Dandreo, Carol J. Etzel, Ann Madsen, Jamie Geier, Heather J. Litman, Arthur Kavanaugh, Andrea Shapiro, Christine J. Barr, Clifton O. Bingham, Alina Onofrei, Joel M. Kremer, Carol A. Connell
Publikováno v:
Oral Presentations.
Background: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Real-world data (RWD) complement clinical trial data in assessing long-term safety. To our knowledge, this is the first long-term comparative RWD analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a281638fb7375b83a92cdb564e24fec2
https://doi.org/10.1136/annrheumdis-2019-eular.621
https://doi.org/10.1136/annrheumdis-2019-eular.621
Autor:
Adeline Ruyssen-Witrand, Gustavo Citera, M. Cros, Jose Luis Rivas, Andrea Shapiro, D. Chapman, Claire Daien, J. Morel, Juergen Wollenhaupt, Cédric Lukas, Christophe Richez
Publikováno v:
Annals of the Rheumatic Diseases. 80:1148.1-1149
Background:A prior post hoc analysis of tofacitinib clinical trial data reported improvements in rheumatoid arthritis (RA) outcomes with tofacitinib vs placebo (PBO) through Month (M)6, regardless of baseline (BL) body mass index (BMI).1Objectives:To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e07a0bcdf73fe8b449302c680e3767e6
https://doi.org/10.1136/annrheumdis-2021-eular.360
https://doi.org/10.1136/annrheumdis-2021-eular.360